Viatris (VTRS) Retained Earnings (2019 - 2026)
Viatris' (VTRS) quarterly Retained Earnings came in at $18.7 billion in Q1 2026, down 1.57% year-on-year from $19.0 billion in Q1 2025, and down 0.73% quarter-over-quarter from $18.8 billion in Q4 2025.
Viatris (VTRS) Retained Earnings (2019 - 2026) Analysis & Trends
Viatris' Retained Earnings history runs 8 years deep, the most recent figure standing at $18.7 billion for Q1 2026.
- On a quarterly basis, Retained Earnings fell 1.57% year-over-year to $18.7 billion in Q1 2026; TTM through Mar 2026 was $18.7 billion, a 1.57% decrease from a year earlier, with the FY2025 full-year figure at $18.8 billion, down 0.64% from the prior year.
- Retained Earnings declined to $18.7 billion in Q1 2026 per VTRS's latest filing, from $18.8 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $19.0 billion in Q1 2025 and bottomed at -$3.8 billion in Q3 2022.
- The 5-year median for Retained Earnings is -$2.7 billion (2025), against an average of $6.1 billion.
- Across the five-year window, Retained Earnings tumbled 155.39% in 2022 and soared 781.4% in 2023, its largest moves.
- Year by year, Retained Earnings stood at -$2.8 billion in 2022, then soared by 781.4% to $18.8 billion in 2023, then grew by 0.57% to $18.9 billion in 2024, then decreased by 0.64% to $18.8 billion in 2025, then fell by 0.73% to $18.7 billion in 2026.
- Per Business Quant, the three latest VTRS Retained Earnings figures stand at $18.7 billion (Q1 2026), $18.8 billion (Q4 2025), and $18.9 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | 37.04 Bn |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 28.20 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 1.11 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 4.54 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 8.83 Bn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | -413.76 Mn |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 18.66 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 589.60 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | -2.13 Bn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | -319.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.66 Bn |
| Dec 31, 2025 | 18.80 Bn |
| Sep 30, 2025 | 18.89 Bn |
| Jun 30, 2025 | -2.66 Bn |
| Mar 31, 2025 | 18.96 Bn |
| Dec 31, 2024 | 18.92 Bn |
| Sep 30, 2024 | 18.89 Bn |
| Jun 30, 2024 | -2.98 Bn |
| Mar 31, 2024 | -2.94 Bn |
| Dec 31, 2023 | 18.81 Bn |
| Sep 30, 2023 | -3.21 Bn |
| Jun 30, 2023 | -3.01 Bn |
| Mar 31, 2023 | -2.76 Bn |
| Dec 31, 2022 | -2.76 Bn |
| Sep 30, 2022 | -3.76 Bn |
| Jun 30, 2022 | -2.90 Bn |
| Mar 31, 2022 | -2.06 Bn |
| Dec 31, 2021 | -1.74 Bn |
| Sep 30, 2021 | -1.47 Bn |
| Jun 30, 2021 | -1.21 Bn |